CYP3A4
Cytochroma P450 CYP3A4 (-atis, n.) (Numerus EC: 1.14.13.97) est haemoproteinum et pars gregis Cytochroma P450 ideo in metabolismo xenobioticorum interest. CYP3A4 maxime omnium cytochromatum iecoris humani exprimatur[1].
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt. |
Locus
recenserePharmaca ad CYP3A4 relata
recensereMulta chemotherapeutica, analgetica, cardiaca, psychopharmaca substratum cytochromatis 3A4 sunt. Inhibitores ut proteasis inhibitores (SCDI!) effectus substratorum augere possunt.
Substrati | Inhibitores[4] | Inductores[5] |
---|---|---|
|
|
|
Notae
recensere- ↑ Liddle, C; Goodwin, BJ; George, J; Tapner, M; Farrell GC (July 2003). "Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes". J Clin Endocrinol Metab 83 (7): 2411-6
- ↑ Cozza KL, Armstrong SC (2001). The Cytochrome P450 System. Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing
- ↑ Preskorn SH (1996). Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. 1st ed.: Professional Communications, Inc.
- ↑ Inhibitor cum subtratorum effectibus fortioribus
- ↑ Inductor cum subtratorum effectibus minoribus
- ↑ Yuji Horikiri; Takehiko Suzuki; Masakazu Mizobe (March 1998). "Pharmacokinetics and metabolism of bisoprolol enantiomers in humans". Journal of Pharmaceutical Sciences 87 (3): 289–294
- ↑ Gandhi S, Fleet JL, Bailey DG, McArthur 4, Wald R, Rehman F2, Garg AX (dec 2013). "Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury". JAMA 18 (23): 2544-53
- ↑ Kronbach, T; Fischer, V; Meyer UA (June 1988). "Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.". Clin Pharmacol Ther 43 (6): 630-5
- ↑ Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED (1995). "Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism". Drug Metab Dispos 23 (4): 490-6
- ↑ 10.0 10.1 Apixabanum et Rivaroxabanum / P-gp et inductores fortes CYP3A4 (Anglice)
- ↑ Apixabani interactionum effectus (Anglice)